Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesFRA:IX1 -4.46%97 Forward PE Ratio is 38.70 as of Jul. 16, 2026. GuruFocus rates FRA:IX1 with a GF Score™ of 97/100 and a GF Value™ of €535.69 (Modestly Undervalued). Among 87 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 73.56% on this metric.
IDEXX Laboratories (FRA:IX1) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
IDEXX Laboratories Forward PE Ratio Related Terms
IDEXX Laboratories Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories Forward PE Ratio Chart
IDEXX Laboratories Annual Data
Trend
2015-12
2016-12
2017-12
2018-12
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
34.84
41.32
44.64
40.49
48.54
72.99
67.57
47.62
55.25
35.29
46.24
IDEXX Laboratories Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
34.84
31.55
40.98
41.32
41.32
52.63
53.19
43.48
44.64
46.51
52.08
51.28
40.49
46.08
56.82
49.75
48.54
41.15
67.11
59.52
72.99
63.29
75.19
77.52
67.57
57.80
40.65
35.34
47.62
56.50
53.19
42.19
55.25
48.78
45.05
44.84
35.29
33.86
41.77
43.47
46.24
40.43
FRA:IX1 vs A, NTRA, WAT: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
IDEXX Laboratories (FRA:IX1) has a Forward PE Ratio of 38.70 as of Jul. 16, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on IDEXX Laboratories and its competitors. According to the industry distribution chart, IDEXX Laboratories ranks #64 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 73.6%.
Is IDEXX Laboratories' Forward PE Ratio too high?
IDEXX Laboratories' current Forward PE Ratio is 38.70. The Medical Diagnostics & Research industry median Forward PE Ratio is 21.53. IDEXX Laboratories' value of 38.70 is 79.7% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #64 out of 87 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IDEXX Laboratories has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Forward PE Ratio compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #64 out of 87 companies for Forward PE Ratio. This places IDEXX Laboratories in the lower half of its industry. The industry median Forward PE Ratio is 21.53. IDEXX Laboratories' value of 38.70 is 79.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 21.53, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current Forward PE Ratio of 38.70 is 79.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 21.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current Forward PE Ratio is 38.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €535.69, compared to a current price of €470.80 — trading 12.1% below its estimated fair value. The current Forward PE Ratio is 38.70 and 79.7% above the Medical Diagnostics & Research industry median of 21.53. IDEXX Laboratories' overall GF Score™ is 97/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Forward PE Ratio is 38.70 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €470.80 is trading 12.1% below its estimated GF Value™ of €535.69.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
Forward PE Ratio: 38.70
GF Value™: €535.69 vs. price of €470.80 (12.1% below fair value)
Industry Position: 79.7% above the Medical Diagnostics & Research median (#64 of 87)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
97GF Score
Get the complete analysis for FRA:IX1
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
